Program
parunoflast
A development code. Also written as “LY5625573”, “VTX3232 30 mg” and “VTX3232”.
Its studies are mostly in Obesity · Parkinson Disease, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 31 open or running | phase 2since Aug 13, 2024 | Aug 13, 2024 | Jan 2027phase 1 · NCT07867340 |
- Named in Eli Lilly’s own pipeline as
Parunoflast (VTX3232)
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 13, 2024First study: phase 2 study in Parkinson DiseaseFirst studyNCT06556173 · 11 enrolled · United States
- Jan 8, 2025Phase 2 study in ObesityNCT06771115 · 175 enrolled · United States
- Oct 5, 2026Phase 1 study in C-Reactive ProteinNCT07867340 · 96 planned · United States, Singapore
Ahead
- Jan 2027Primary completion: phase 1 study in C-Reactive ProteinNCT07867340
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07867340C-Reactive Protein · United States, Singapore | 1 | Not yet recruiting | Jan 2027 | 96 |
| NCT06771115Obesity · United States | 2 | Completed | Sep 10, 2025 | 175 |
| NCT06556173Parkinson Disease · United States | 2 | Completed | Apr 4, 2025 | 11 |
How it is read
Names in the registry
- “LY5625573”, 1 entry
- “VTX3232 30 mg”, 1 entry
- “VTX3232”, 1 entry
Codes read as this program: LY5625573, VTX3232.
Conditions, from the studies’ own filings
- Obesity, 1 study
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.